Neglected Diseases clinical trials
The registry lists 41 studies for Neglected Diseases across more than 10 countries. 8 are recruiting or about to start. 8 of them are mainly about Neglected Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Neglected Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Drugs for Neglected Diseases (5) · Baylor College of Medicine (4) · Institute of Tropical Medicine, Belgium (3) · Emory University (3) · Tulane University (2) · Lihir Medical Centre (2) · Swiss Tropical & Public Health Institute (2) · Kenya Medical Research Institute (1)
What is being tested here
Drugs under test in Neglected Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) · Murdoch Childrens Research Institute
- Jul 2027Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations · Uwemedimo Friday Ekpo
- Sep 2027Prospective Evaluation of Rapid Diagnostic Tests for Trypanosoma Cruzi Infection · Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
Who these studies take
Of the 5 Neglected Diseases studies recruiting now, 3 (60%) set no upper age limit and 2 (40%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (60%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (80%) | 4 (80%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 4 (80%) | 4 (80%) |
| 85 | 3 (60%) | 3 (60%) |
Across all 41 studies, recruiting or not: 54% stop at 75 or younger and 49% at 65; 46% take children; 2% are for women only and 7% for men only; 54% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 41 of 41. search them.
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- Expanding Access to Preventive Chemotherapy Among Mobile and Migrant PopulationsRecruitingNCT07707817Not applicable1 country
- Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health WorkersNot yet recruitingNCT07506967Not applicable5 countries
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Prospective Evaluation of Rapid Diagnostic Tests for Trypanosoma Cruzi InfectionRecruitingNCT073043491 country
- Efficacy and Tolerability of Adjunct Metformin for Multibacillary LeprosyRecruitingNCT05243654Phase 21 country
- Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income CountriesNot yet recruitingNCT06989502Not applicable3 countries
- Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal NeurocysticercosisNot yet recruitingNCT06376396Phase 4
- Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)Active, not recruitingNCT05500326Phase 21 country
- Digital Toolkit for Skin Diseases in LMICs: Part 2CompletedNCT06292260Not applicable1 country
- Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationCompletedNCT06350851Not applicable1 country
- ARN-75039 Lassa Fever Treatment in West AfricaSuspendedNCT07419373Phase 22 countries
- Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate TabletsCompletedNCT06606860Phase 11 country
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpGCompletedNCT02143518Phase 11 country
- Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central AfricaWithdrawnNCT04035174Not applicable1 country
- Fexinidazole in Human African Trypanosomiasis Due to T. b. RhodesienseCompletedNCT03974178Phase 2/32 countries
- Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in EthiopiaCompletedNCT053320931 country
- Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease TherapyStatus unknownNCT05169554Phase 21 country
- Emodepside Phase II Trial for Treatment of OnchocerciasisActive, not recruitingNCT05180461Phase 22 countries
- Adoption of L-PZQ for Schistosomiasis by Endemic Counties - Social Science Research StudyActive, not recruitingNCT053504623 countries
- Assessment of Recombinant HAT-RDT SpecificityCompletedNCT056376321 country
- PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole TabletsCompletedNCT04920292Phase 11 country
- Digital Toolkit for Skin Diseases in LMICsStatus unknownNCT05300399Not applicable1 country
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlStatus unknownNCT04844905Phase 31 country
- Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese AdultsCompletedNCT03373214Phase 11 country
- First in Man Clinical Trial of Emodepside (BAY 44-4400)CompletedNCT02661178Phase 11 country
- Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy AdultsCompletedNCT01717950Phase 11 country
- The Impact of Enhanced, Demand-side Sanitation and Hygiene Promotion on Sustained Behavior Change and Health in EthiopiaCompletedNCT03075436Not applicable1 country
- Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )CompletedNCT03676140Phase 31 country
- Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan AfricaCompletedNCT034583381 country
- Zambia One Love Aim 3 TrialCompletedNCT02744586Not applicable1 country
- Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in MoroccoCompletedNCT029790021 country
- Serum Pharmacokinetic Disposition and Urinary Excretion of AlbendazoleCompletedNCT03192449Phase 1
- Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese AdultsCompletedNCT02126462Phase 11 country
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the FexinidazoleCompletedNCT00982904Phase 11 country
- Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRCCompletedNCT01589289Phase 31 country
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158CompletedNCT01533961Phase 11 country
- Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic FilariasisWithdrawnNCT01903057Phase 41 country
- Does Treating Hookworm Improve Productivity of Small Subsistence FarmersStatus unknownNCT02102321Not applicable1 country
- Single-dose Azithromycin for the Treatment of YawsCompletedNCT01382004Phase 31 country
- Population Pharmacokinetics of Benznidazole in Children With Chagas DiseaseCompletedNCT00699387Not applicable1 country